MetaVia Announces Upcoming Presentation at the H.C. Wainwright Virtual Conference on Liver Disease
MetaVia Inc., a pioneering clinical-stage biotechnology company listed on Nasdaq under the ticker MTVA, is preparing for a significant presentation at the upcoming H.C. Wainwright Liver Disease Virtual Conference taking place from October 21 to 22, 2025. The company aims to detail its innovative strategies in addressing cardiometabolic diseases during this event, which will be attended by institutional investors and key industry stakeholders.
Hyung Heon Kim, the President and CEO of MetaVia, will lead the presentation, showcasing the company's promising pipeline aimed at transforming treatment approaches to obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In addition, Chief Financial Officer Marshall H. Woodworth is scheduled to engage in one-on-one meetings with interested investors. Registered participants of the conference can log into the H.C. Wainwright event platform to set up meetings with MetaVia’s management team, facilitating direct communication between the company and potential investors.
MetaVia is at the forefront of developing groundbreaking therapies, including the lead candidate DA-1726, which targets obesity through a unique mechanism of action. This candidate is an oxyntomodulin (OXM) analogue that simultaneously activates both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). By mimicking the natural gut hormone OXM, DA-1726 aims to effectively reduce food intake while boosting energy expenditure. Preliminary Phase 1 clinical trial results indicate that DA-1726 may lead to superior weight loss, improved glycemic control, and significant waist reduction compared to traditional treatments.
Another notable asset in MetaVia's pipeline is DA-1241, a novel G-protein-coupled receptor 119 (GPR119) agonist that shows promise in treating MASH. This innovative compound has demonstrated the ability to promote the secretion of vital gut peptides such as GLP-1, GIP, and PYY. Preclinical studies have suggested that DA-1241 could positively impact liver health by diminishing inflammation and combatting issues related to lipid metabolism, thereby reducing hepatic steatosis and liver fibrosis while enhancing glucose control. A Phase 2a clinical study has already shown that DA-1241 facilitates direct hepatic action alongside its glucose-lowering properties, positioning it as a key player in MetaVia's therapeutic portfolio.
For investors looking to learn more about MetaVia’s groundbreaking solutions and future directions, additional information can be acquired by visiting the company's official website at www.metaviatx.com. Alternatively, those interested in scheduling a meeting with management outside of the conference can reach out to Michael Miller via email. As the landscape of cardiometabolic disease treatments continues to evolve, MetaVia stands out as a hopeful contender with its innovative approaches and commitment to addressing critical health challenges.
In closing, the H.C. Wainwright Liver Disease Virtual Conference represents an essential platform for MetaVia to connect with investors, share insights about its innovative pipeline, and potentially attract new partnerships that could advance its mission in transforming how cardiometabolic diseases are treated. With its promising candidates like DA-1726 and DA-1241, the company continues to pave the way toward enhanced treatment options for patients suffering from obesity and related conditions.
Hyung Heon Kim, the President and CEO of MetaVia, will lead the presentation, showcasing the company's promising pipeline aimed at transforming treatment approaches to obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In addition, Chief Financial Officer Marshall H. Woodworth is scheduled to engage in one-on-one meetings with interested investors. Registered participants of the conference can log into the H.C. Wainwright event platform to set up meetings with MetaVia’s management team, facilitating direct communication between the company and potential investors.
MetaVia is at the forefront of developing groundbreaking therapies, including the lead candidate DA-1726, which targets obesity through a unique mechanism of action. This candidate is an oxyntomodulin (OXM) analogue that simultaneously activates both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). By mimicking the natural gut hormone OXM, DA-1726 aims to effectively reduce food intake while boosting energy expenditure. Preliminary Phase 1 clinical trial results indicate that DA-1726 may lead to superior weight loss, improved glycemic control, and significant waist reduction compared to traditional treatments.
Another notable asset in MetaVia's pipeline is DA-1241, a novel G-protein-coupled receptor 119 (GPR119) agonist that shows promise in treating MASH. This innovative compound has demonstrated the ability to promote the secretion of vital gut peptides such as GLP-1, GIP, and PYY. Preclinical studies have suggested that DA-1241 could positively impact liver health by diminishing inflammation and combatting issues related to lipid metabolism, thereby reducing hepatic steatosis and liver fibrosis while enhancing glucose control. A Phase 2a clinical study has already shown that DA-1241 facilitates direct hepatic action alongside its glucose-lowering properties, positioning it as a key player in MetaVia's therapeutic portfolio.
For investors looking to learn more about MetaVia’s groundbreaking solutions and future directions, additional information can be acquired by visiting the company's official website at www.metaviatx.com. Alternatively, those interested in scheduling a meeting with management outside of the conference can reach out to Michael Miller via email. As the landscape of cardiometabolic disease treatments continues to evolve, MetaVia stands out as a hopeful contender with its innovative approaches and commitment to addressing critical health challenges.
In closing, the H.C. Wainwright Liver Disease Virtual Conference represents an essential platform for MetaVia to connect with investors, share insights about its innovative pipeline, and potentially attract new partnerships that could advance its mission in transforming how cardiometabolic diseases are treated. With its promising candidates like DA-1726 and DA-1241, the company continues to pave the way toward enhanced treatment options for patients suffering from obesity and related conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.